AndreaBozzo/ceres-open-data-index huggingface dataset:
National Survey on Drug Use and Health (NSDUH), 2002

<p>The National Survey on Drug Use and Health (NSDUH) series (formerly titled National Household Survey on Drug Abuse) primarily measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions included age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covers substance abuse treatment history and perceived need for treatment, and includes questions from the Diagnostic and Statistical Manual (DSM) of Mental Disorders that allow diagnostic criteria to be applied. The survey included questions concerning treatment for both substance abuse and mental health-related disorders. Respondents were also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing.</p>
 <ul><li>National Survey on Drug Use and Health, 2002 (ICPSR 3903): http://www.icpsr.umich.edu/icpsrweb/ICPSR/series/64/studies/3903?archive=ICPSR&sortBy=7</li><li>National Survey on Drug Use and Health, 2003 (ICPSR 4138): http://www.icpsr.umich.edu/icpsrweb/ICPSR/series/64/studies/4138?archive=ICPSR&sortBy=7</li></ul>
Extracorporeal membrane oxygenation for severe acute respiratory failure

Extracorporeal membrane oxygenation (ECMO) is a technique for providing life support, in case the natural lungs are failing and are not able to maintain a sufficient oxygenation of the body's organ systems. ECMO technique was an adaptation of conventional cardiopulmonary bypass technique and introduced into treatment of severe acute respiratory distress syndrome (ARDS) in the 1970s. The intial reports of the use of ECMO in ARDS patients were quite enthusiastic, however, in the following years it became clear that ECMO was only of benefit in newborns with acute respiratory failure. In neonates treated with ECMO, survival rates of 80% could be achieved. In adult patients with ARDS, two large randomized controlled trials (RCTs) published in 1979 and 1994 failed to show an advantage of ECMO over convential treatment, survival rates were only 10% and 33%, respectively, in the ECMO groups. Since then, ECMO technology as well as conventional treatment of adult ARDS have undergone further improvements.  In conventional treatment lung-protective ventilation strategies were introduced and ECMO was made safer by applying heparin-coated equipment, membranes and tubings. Many ECMO centres now use these advanced ECMO technology and report survival rates in excess of  50% in uncontrolled data collections. The question, however, of whether the improved ECMO can really challenge the advanced conventional treatment of adult ARDS is unanswered and will need evaluation by a future RCT.
Compound 525198: Chloromethyl 2-chloropentanoate

Chemical compound data from PubChem database. IUPAC Name: chloromethyl 2-chloropentanoate. Molecular Formula: C6H10Cl2O2. Molecular Weight: 185.05. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Managed Long-Term Care Performance Data: Beginning 2014

The Managed Long-Term Care (MLTC) performance data is an annual evaluation (semi-annual prior to 2022) of New York state-certified MLTC plans. Rates are calculated for each performance measure by plan and describe their population, quality of care, and enrollees’ satisfaction. These data also present the statewide demographic profile of MLTC enrollees and statewide rates of emergency room, hospital, and nursing home utilization. Refer to the Measures document to learn more about specific MLTC measures. In the future, as more evaluations are performed, measures can be trended over time. Refer to the Overview document for information on the data sources, time frames, and limitations of this dataset.
Volumetric computerized tomography as a measurement of periprosthetic acetabular osteolysis and its correlation with wear

Osteolysis, which is considered to be a major source of morbidity following total hip joint replacement, has been notoriously difficult to measure accurately, particularly in the acetabular area. In order to study periacetabular osteolysis, specialized software for computerized tomography (CT) scan image analysis has been developed. This software (3D-CT) eliminates metal artifacts, allows three-dimensional segmentation of the CT image, and reconstructs the segmented image to provide an accurate representation and measurement of volume for osteolytic lesions. In the present study, 20 patients underwent periacetabular osteolytic volume determination using 3D-CT, functional assessment (using the Harris Hip Scale, the Western Ontario and McMaster University Osteoarthritis Index, and the short form 36 questionnaire), and two-dimensional analysis of volumetic polyethylene wear using digitalized plain films. Periacetabular osteolysis correlated directly with the polyethylene wear rate (relative risk [RR] = 0.494, P = 0.027). If one patient with an acetabular revision, one patient with recurrent dislocation, and one patient with a Biomet prosthesis are excluded, then the correlation between wear and osteolysis is improved (RR = 0.685, P = 0.002). In summary, the current study demonstrates both the feasibility of CT imaging of periacetabular osteolysis and the correlation between polyethylene wear and osteolytic volume, providing a potential outcome measure for clinical trials that are designed to examine interventions in this complex disease process.
Evaluation of the fall protection of Type I industrial helmets

Type I industrial helmets have been widely used at construction sites and by manufacturers as “general purpose” safety helmets. The performance of Type I industrial helmets for fall protection is not required to be tested in standardized tests. Chin straps and suspension system adjustment mechanisms are two important components of a typical industrial helmet, but the effects of proper use of them on the protective performance of Type I helmets have not been evaluated. The current study was designed to analyze the fall protection performance of Type I industrial helmets and to evaluate if the use of a chin strap and the suspension system tightness have any effect on protection performance. Head impact tests were performed by letting an instrumented manikin free fall backwards, from a standing posture, so that the manikin would make head-first contact with a solid surface of two different materials (concrete and plywood-covered). The results showed that all four tested helmet models demonstrated excellent performances for fall protection compared to the control group without wearing helmets. The fall protection performance of the advanced helmet models was substantially better than the basic helmet models. However, the effects of the use of chin straps and suspension system tightness on the helmets’ fall protection performance were statistically not significant. The findings of our study provide information to help construction companies and manufacturers better manage the use of Type I helmets for fall protection, thereby reducing work-related traumatic brain injury risks.
Compound 528125: 2-Methyl-5-(2-methylbutyl)-3-octylpyrazine

Chemical compound data from PubChem database. IUPAC Name: 2-methyl-5-(2-methylbutyl)-3-octylpyrazine. Molecular Formula: C18H32N2. Molecular Weight: 276.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401642-T1: [Translated] METHOD FOR LINEING UP PLANES DURING LANDING APPROACH

Many types of vehicle disturb the environment behind them as they proceed. As a result, a delay between two successive vehicles has to be maintained to avoid a situation where following vehicles are adversely affected by the disturbed environment caused by leading vehicles. Previously, sequencing has been carried out on a "first come, first served" basis but this is not satisfactory. A method of sequencing a plurality of vehicles is disclosed, wherein each candidate vehicle in said plurality of candidate vehicles is a candidate to be allocated the next place in a sequence, said method comprising the steps of: (i) receiving information pertaining to one of said candidate vehicles; (ii) calculating a value to be attributed to said candidate vehicle on the basis of said received information and information received from the candidate vehicle most recently allocated a place in said sequence; (iii) repeating steps (i) and (ii) for each of said candidate vehicles; (iv) selecting one of said candidate vehicles based on said attributed values; and (v) allocating said selected candidate vehicle the next place in said sequence.
Drug Abuse Warning Network (DAWN-2004)

<p>The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.<br />
DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.<br />
The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year.  Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.This study has 1 Data Set.</p>
Characterization of DNA binding, transcriptional activation, and regulated nuclear association of recombinant human NFATp

Background
          NFATp is one member of a family of transcriptional activators whose nuclear accumulation and hence transcriptional activity is regulated in mammalian cells. Human NFATp exists as a phosphoprotein in the cytoplasm of naive T cells. Upon antigen stimulation, NFATp is dephosphorylated, accumulates in nuclei, and functions to regulate transcription of genes including those encoding cytokines. While the properties of the DNA binding domain of NFATp have been investigated in detail, biochemical studies of the transcriptional activation and regulated association with nuclei have remained unexplored because of a lack of full length, purified recombinant NFATp.
        
        
          Results
          We developed methods for expressing and purifying full length recombinant human NFATp that has all of the properties known to be associated with native NFATp. The recombinant NFATp binds DNA on its own and cooperatively with AP-1 proteins, activates transcription in vitro, is phosphorylated, can be dephosphorylated by calcineurin, and exhibits regulated association with nuclei in vitro. Importantly, activation by recombinant NFATp in a reconstituted transcription system required regions of the protein outside of the central DNA binding domain.
        
        
          Conclusions
          We conclude that NFATp is a bona fide transcriptional activator. Moreover, the reagents and methods that we developed will facilitate future studies on the mechanisms of transcriptional activation and nuclear accumulation by NFATp, a member of an important family of transcriptional regulatory proteins.
Future of adenoviruses in the gene therapy of arthritis

Recombinant adenoviruses are straightforward to produce at high titres, have a promiscuous host-range, and, because of their ability to infect nondividing cells, lend themselves to in vivo gene delivery. Such advantages have led to their widespread and successful use in preclinical studies of arthritis gene therapy. While adenoviral vectors are well suited to 'proof of principle' experiments in laboratory animals, there are several barriers to their use in human studies at this time. Transient transgene expression limits their application to strategies, such as synovial ablation, which do not require extended periods of gene expression. Moreover, there are strong immunological barriers to repeat dosing. In addition, safety concerns predicate local, rather than systemic, delivery of the virus. Continued engineering of the adenoviral genome is producing vectors with improved properties, which may eventually overcome these issues. Promising avenues include the development of 'gutted' vectors encoding no endogenous viral genes and of adenovirus–AAV chimeras. Whether these will offer advantages over existing vectors, which may already provide safe, long-term gene expression following in vivo delivery, remains to be seen.
Compound 525624: N,N-Dimethyl-N'-decyl-p-methoxybenzamidine

Chemical compound data from PubChem database. IUPAC Name: N'-decyl-4-methoxy-N,N-dimethylbenzenecarboximidamide. Molecular Formula: C20H34N2O. Molecular Weight: 318.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399753-T1: [Translated] AMIDES AS PYRUVATE DEHYDROGENASE INHIBITORS

A compound of formula (I):wherein:Ring A is a nitrogen linked mono or bicyclic heterocyclic ring as defined within;R<1 >and R<2 >are independently C1-3alkyl optionally substituted by fluoro or chloro;or R<1 >and R<2 >together with the carbon atom to which they are attached, form a C3-5cycloalkyl ring optionally substituted by fluoro;R<3 >is defined within; andn is 0-5; wherein the values of R<3 >may be the same or different;or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof is described. The use of compounds of formula (I) in the production of an elevation of PDH activity in a warm-blooded animal such as a human being are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.
Clofarabine

Clofarabine is an intravenous injection used to treat relapsed or refractory acute lymphoblastic leukemia, particularly in pediatric patients. It belongs to the class of nucleoside metabolic inhibitors, which work by stopping cancer cells from multiplying. Manufactured by Eugia US LLC under ANDA212457, this 1 mg/mL solution is now discontinued. This information was generated using AI and is provided for informational and research purposes only.
Compound 528135: 5-Isobutyl-3-methyl-2-methoxypyrazine

Chemical compound data from PubChem database. IUPAC Name: 2-methoxy-3-methyl-5-(2-methylpropyl)pyrazine. Molecular Formula: C10H16N2O. Molecular Weight: 180.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525393: 2,6-Dimethyl-4-ethyl-3,5-dithiaheptane

Chemical compound data from PubChem database. IUPAC Name: 1,1-bis(propan-2-ylsulfanyl)propane. Molecular Formula: C9H20S2. Molecular Weight: 192.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Pantoprazole sodium

Pantoprazole Sodium is a prescription proton pump inhibitor used to reduce stomach acid production. This intravenous powder for injection, containing 40 mg per vial, is manufactured by Hikma Pharmaceuticals USA Inc. and approved under NDA209463. It's typically used for conditions like gastroesophageal reflux disease (GERD) or ulcers when oral forms aren't suitable. This information was generated using AI and is provided for informational and research purposes only.
Compound 529445: Indane, 1-(2-phenylethyl)

Chemical compound data from PubChem database. IUPAC Name: 1-(2-phenylethyl)-2,3-dihydro-1H-indene. Molecular Formula: C17H18. Molecular Weight: 222.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
CMS Program Statistics - Medicare Advantage-Skilled Nursing Facility

The CMS Program Statistics - Medicare Advantage, Skilled Nursing Facility tables provide utilization data for skilled nursing facilities, by Medicare Advantage beneficiaries.

For additional information on enrollment, providers, and Medicare use and payment, visit the CMS Program Statistics page.

 

Below is the list of tables:


	MDCR SNF MA 1.  Medicare Skilled Nursing Facilities: Utilization for Medicare Advantage Beneficiaries, by Type of Entitlement, Yearly Trend
	MDCR SNF MA 2.  Medicare Skilled Nursing Facilities: Utilization for Medicare Advantage Beneficiaries, by Demographic Characteristics and Medicare-Medicaid Enrollment Status
	MDCR SNF MA 3.  Medicare Skilled Nursing Facilities: Utilization for Medicare Advantage Beneficiaries, by Area of Residence
Compound 527847: 2,4-Dichlorobenzyl nonyl ether

Chemical compound data from PubChem database. IUPAC Name: 2,4-dichloro-1-(nonoxymethyl)benzene. Molecular Formula: C16H24Cl2O. Molecular Weight: 303.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Succinylcholine chloride

Succinylcholine Chloride is a generic prescription drug used as a muscle relaxant during surgery or medical procedures. It's administered via injection (intramuscular or intravenous) at a strength of 20 mg/mL. Manufactured by Eugia US LLC under ANDA 217808, it's available in 10 mL multi-dose vials and was marketed starting October 2023, but is now discontinued. This information was generated using AI and is provided for informational and research purposes only.
2011-2012 NSDUH State Prevalence Estimates – Individual Excel Tables by Outcome

These are 2011-2012 NSDUH State estimates. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Results are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Patent AT-E400383-T1: [Translated] HEATING TO CONTROL THE SOLIDIFICATION OF A CAST STRUCTURE

A method for the production of a cast component comprising the steps of:1) providing a molten metal mass in a casting mold and exposing the casting mold to a cooling environment thereby creating a solidification interface between molten metal regions and solidified metal regions, and2) applying at least one focused energy source either to a portion of the filled casting mold to control a temperature gradient near the solidification interface.
Compound 526941: 2-Methyl-3-thienyl 2-thienyl disulphide

Chemical compound data from PubChem database. IUPAC Name: 2-methyl-3-(thiophen-2-yldisulfanyl)thiophene. Molecular Formula: C9H8S4. Molecular Weight: 244.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526609: 3-O-Acetyl-2,6-anhydro-1,4,5-tri-O-methylhexitol

Chemical compound data from PubChem database. IUPAC Name: [4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl] acetate. Molecular Formula: C11H20O6. Molecular Weight: 248.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.